These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Mira E; Guidetti G; Ghilardi L; Fattori B; Malannino N; Maiolino L; Mora R; Ottoboni S; Pagnini P; Leprini M; Pallestrini E; Passali D; Nuti D; Russolo M; Tirelli G; Simoncelli C; Brizi S; Vicini C; Frasconi P Eur Arch Otorhinolaryngol; 2003 Feb; 260(2):73-7. PubMed ID: 12582782 [TBL] [Abstract][Full Text] [Related]
4. [A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease]. Parfenov VA; Zamergrad MV; Kazei DV; Nauta J Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):42-48. PubMed ID: 33459540 [TBL] [Abstract][Full Text] [Related]
5. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study. Novotný M; Kostrica R Int Tinnitus J; 2002; 8(2):115-23. PubMed ID: 14763223 [TBL] [Abstract][Full Text] [Related]
6. Positive pressure therapy for Ménière's disease or syndrome. van Sonsbeek S; Pullens B; van Benthem PP Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD008419. PubMed ID: 25756795 [TBL] [Abstract][Full Text] [Related]
7. Report from a Consensus Conference on the treatment of Ménière's disease with betahistine: rationale, methodology and results. Casani AP; Guidetti G; Schoenhuber R; Acta Otorhinolaryngol Ital; 2018 Oct; 38(5):460-467. PubMed ID: 30498275 [TBL] [Abstract][Full Text] [Related]
8. Effect of transtympanic low-pressure therapy in patients with unilateral Menière's disease unresponsive to betahistine: a randomised, placebo-controlled, double-blinded, clinical trial. Gürkov R; Filipe Mingas LB; Rader T; Louza J; Olzowy B; Krause E J Laryngol Otol; 2012 Apr; 126(4):356-62. PubMed ID: 22365373 [TBL] [Abstract][Full Text] [Related]
9. Hearing function after betahistine therapy in patients with Ménière's disease. Seyed Tootoonchi SJ; Ghiasi S; Shadara P; Samani SM; Fouladi DF Braz J Otorhinolaryngol; 2016; 82(5):500-6. PubMed ID: 26810620 [TBL] [Abstract][Full Text] [Related]
10. Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease. Ganança MM; Caovilla HH; Ganança FF Acta Otolaryngol; 2009 May; 129(5):487-92. PubMed ID: 18615332 [TBL] [Abstract][Full Text] [Related]
11. Betahistine in Ménière's Disease or Syndrome: A Systematic Review. Van Esch B; van der Zaag-Loonen H; Bruintjes T; van Benthem PP Audiol Neurootol; 2022; 27(1):1-33. PubMed ID: 34233329 [TBL] [Abstract][Full Text] [Related]
12. Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience. Monzani D; Barillari MR; Alicandri Ciufelli M; Aggazzotti Cavazza E; Neri V; Presutti L; Genovese E Acta Otorhinolaryngol Ital; 2012 Dec; 32(6):393-403. PubMed ID: 23349559 [TBL] [Abstract][Full Text] [Related]
14. Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial. Strupp M; Hupert D; Frenzel C; Wagner J; Hahn A; Jahn K; Zingler VC; Mansmann U; Brandt T Acta Otolaryngol; 2008 May; 128(5):520-4. PubMed ID: 18421605 [TBL] [Abstract][Full Text] [Related]
15. Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. Strupp M; Kraus L; Schautzer F; Rujescu D J Neurol; 2018 Oct; 265(Suppl 1):80-85. PubMed ID: 29532287 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo. Nauta JJ Eur Arch Otorhinolaryngol; 2014 May; 271(5):887-97. PubMed ID: 23778722 [TBL] [Abstract][Full Text] [Related]
17. Lifestyle and dietary interventions for Ménière's disease. Webster KE; George B; Lee A; Galbraith K; Harrington-Benton NA; Judd O; Kaski D; Maarsingh OR; MacKeith S; Murdin L; Ray J; Van Vugt VA; Burton MJ Cochrane Database Syst Rev; 2023 Feb; 2(2):CD015244. PubMed ID: 36848645 [TBL] [Abstract][Full Text] [Related]
18. Using betahistine in the treatment of patients with Menière's disease: a meta-analysis with the current randomized-controlled evidence. Devantier L; Hougaard D; Händel MN; Liviu-Adelin Guldfred F; Schmidt JH; Djurhuus B; Callesen HE Acta Otolaryngol; 2020 Oct; 140(10):845-853. PubMed ID: 32580600 [No Abstract] [Full Text] [Related]
19. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series. Lezius F; Adrion C; Mansmann U; Jahn K; Strupp M Eur Arch Otorhinolaryngol; 2011 Aug; 268(8):1237-1240. PubMed ID: 21626121 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic and surgical therapies for patients with Meniere's disease: A systematic review and network meta-analysis. Ahmadzai N; Cheng W; Kilty S; Esmaeilisaraji L; Wolfe D; Bonaparte J; Schramm D; Fitzpatrick E; Lin V; Skidmore B; Hutton B PLoS One; 2020; 15(9):e0237523. PubMed ID: 32870918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]